---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-26-000011"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2026-05-13T11:04:01+00:00"
generated_at: "2026-05-13T11:07:47.775468+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q1 net loss $26.2M; initiates Phase 2b trial for ALTO-207 in TRD

## Summary
- Net loss of $26.2M for Q1 2026 vs $15.2M in Q1 2025; R&D expenses rose to $20.3M.
- Cash and equivalents of $264.2M as of March 31, 2026, up from $177.0M after $120M PIPE closed in March.
- Phase 2b trial of ALTO-207 in treatment-resistant depression (TRD) initiated; topline data expected 2H 2027.
- ALTO-101 Phase 2 POC trial missed primary endpoint (theta-ITC) but showed significant EEG biomarker effects and attention improvement.
- ALTO-300 and ALTO-100 Phase 2b topline data readouts delayed to 1H 2027 and mid-2027, respectively, due to enhanced patient eligibility review.

## SEC filing metadata
- accession: 0001999480-26-000011
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2026-05-13T11:04:01+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/0001999480-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/alto-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-26-000011
- JSON: https://secwatch.observer/filing/0001999480-26-000011.json
- Plain text: https://secwatch.observer/filing/0001999480-26-000011.txt

## Key facts
- Earnings Releases
  Alto Neuroscience, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 13, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/0001999480-26-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.